Sue Friedman Provides an Overview of the ABOUT Network

Article

Sue Friedman, discusses the ABOUT Network, which is the first-ever patient-powered research registry created and governed by and for people affected by hereditary breast and ovarian cancers.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network, which is the first-ever patient-powered research registry created and governed by and for people affected by hereditary breast and ovarian cancers.

Related Videos
Testi
Patrick Buxton, RN, BSN
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Related Content
gynecologic cancer

Why a Trauma-Informed Approach Is Ideal in Gynecologic Cancer Care

November 29th 2023
Article

Christina M. Wilson, PhD, CRNP, WHNP-BC, shares how providers can help their patients feel empowered during their treatment.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Endometrial Cancer

Patients With Endometrial Cancer Report Maintained HRQOL With Dostarlimab

November 21st 2023
Article

Those receiving dostarlimab experienced numerical improvements from baseline in terms of quality of life, emotional functioning, pain, and back and pelvis pain scores.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

FDA Approves Capivasertib/Fulvestrant for Advanced/Metastatic, HR+, HER2- Breast Cancer

FDA Approves Capivasertib/Fulvestrant for Advanced/Metastatic, HR+, HER2- Breast Cancer

November 16th 2023
Article

The FDA has approved capivasertib plus fulvestrant to treat patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.

cervical cancer

Atezolizumab Combo Reduces Risk of Death by 32% Over Bevacizumab/Chemo in Recurrent Cervical Cancer

November 9th 2023
Article

The median OS achieved with atezolizumab plus bevacizumab and chemotherapy was 32.1 months vs 22.8 months with bevacizumab and chemotherapy alone.

© 2023 MJH Life Sciences

All rights reserved.